← Back to news
Clinical trialCLINICALTRIALSThursday, April 9, 2026 · April 9, 2026

Trial Now Recruiting: Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders (NCT06839469)

WHY IT MATTERS

This trial is now actively recruiting participants with DMD and SMA Type 3, offering a chance to contribute to developing better measurement tools that could help doctors track disease progression and evaluate future treatments more accurately.

Researchers at Columbia University are looking for 106 children and young adults with Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy Type 3 (SMA Type 3) to join a study. The study will use special sensors and technology to track how people walk and move in their daily lives over a long period of time. The goal is to find new ways to measure how these diseases are progressing so doctors can better understand and treat them.

NCT ID: NCT06839469 Status: RECRUITING Conditions: Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD) Enrollment: 106 Sponsor: Columbia University Summary: The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.

YOU CAN ACT ON THIS

If you or your child has DMD or SMA Type 3, contact Columbia University through the trial link (NCT06839469) to learn if you qualify and how to enroll.

Find clinical trials →Learn more ↗
clinical trial recruitingdigital biomarkersmovement monitoringchildhood neuromuscular diseasenatural environment study

Related conditions

Distal spinal muscular atrophy type 3Proximal spinal muscular atrophy type 3X-linked distal spinal muscular atrophy type 3Duchenne muscular dystrophy